Life Science REIT PLC 10.1% potential upside indicated by Jefferies

Life Science REIT PLC with ticker (LON:LABS) now has a potential upside of 10.1% according to Jefferies.

LABS.L

Jefferies set a target price of 36 GBX for the company, which when compared to the Life Science REIT PLC share price of 33 GBX at opening today (06/09/2024) indicates a potential upside of 10.1%. Trading has ranged between 32 (52 week low) and 77 (52 week high) with an average of 431,646 shares exchanging hands daily. The market capitalisation at the time of writing is £114,450,002.

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.